Saturday 17 October 2026
Export PODD’s income statement to Excel — free account
Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
141.10
2.33
+1.68%
Follow PODD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 6 | 6 | 9 |
| 19.68% | 18.12% | 23.00% | 26.02% | ||
| 8.13% | 7.87% | 9.31% | 11.31% | ||
ROIC |
16.64% | 16.94% | 17.90% | 17.56% | |
Return on Tangible Assets |
12.72% | 12.03% | 16.35% | 19.11% | |
Average Days of Receivables |
66.90 | 69.67 | 68.54 | 70.37 | |
Free Cash Flow per Share |
5.79 | 4.97 | 5.54 | 3.83 | |
Free Cash Flow |
407.50 | 349.90 | 387.80 | 265.60 | |
Capital Expenditures |
(126.00) | (219.40) | (231.50) | (245.60) | |
| Other line items | |||||
Cash ROIC |
12.91% | 11.00% | 14.20% | 9.14% | |
Accounts Receivable Turnover |
6.02 | 6.14 | 6.13 | 5.91 | |
Accounts Payable Turnover |
16.26 | 16.21 | 8.11 | 8.05 | |
Inventory Turnover |
1.61 | 1.74 | 1.86 | 1.90 | |
Average Days of Payables |
24.45 | 35.64 | 65.01 | 50.96 | |
Days of Inventory on Hand |
226.38 | 215.05 | 200.73 | 200.35 | |
Tax Rate |
(0.21) | (0.27) | (0.25) | (0.24) | |
Research and Development Expense of Revenue |
10.74% | 11.12% | 11.42% | 11.33% | |
Selling, General and Administrative Expense of Revenue |
43.40% | 43.02% | 42.11% | 42.86% | |
Share Based Compensation of Revenue |
2.47% | 2.32% | 2.27% | 2.55% | |
Interest Coverage |
8.25 | 7.98 | 7.81 | 8.77 | |
Operating CF/Net income |
2.17 | 2.30 | 2.05 | 1.36 | |
Depreciation/Fixed assets |
0.12 | 0.11 | 0.11 | 0.12 | |
Capex/Depreciation |
(1.44) | (2.43) | (2.44) | (2.47) | |
Revenue per Share |
35.84 | 38.50 | 41.45 | 44.06 | |
Operating CF per Share |
7.58 | 8.09 | 8.85 | 7.38 | |
Capex per Share |
(1.79) | (3.12) | (3.31) | (3.54) | |
Capex to Sales |
0.05 | 0.08 | 0.08 | 0.08 |
Columns are period end dates